Molecular Monitoring Improves Survival in Some Patients With Newly Diagnosed Leukemia

Sequential molecular measurable residual disease monitoring, coupled with guided treatment, beneficial for patients with NPM1 and FLT3 mutations
acute lymphoblastic leukemia
Adobe Stock
Medically Reviewed By:
Farrokh Sohrabi, M.D.
Published on
Updated on
Loading content, please wait...

Related Stories

No stories found.
logo
www.healthday.com